1	Basel	basel	NNP	p2=NN	9	npadvmod	9:AM-TMP
2	,	,	,	_	9	punct	_
3	May	may	NNP	_	9	npadvmod	9:AM-TMP
4	19	0	CD	_	3	num	_
5	,	,	,	_	9	punct	_
6	2014	0	CD	_	8	hmod	_
7	-	-	HYPH	p2=,	8	hyph	_
8	Novartis	novartis	NNP	p2=NNPS	9	nsubj	9:A0=PAG
9	announced	announce	VBD	pb=announce.01	0	root	_
10	today	today	NN	_	9	npadvmod	9:AM-TMP
11	the	the	DT	_	12	det	_
12	signing	signing	NN	_	9	dobj	9:A1=PPT
13	of	of	IN	_	12	prep	_
14	a	a	DT	_	18	det	_
15	licensing	licensing	NN	_	18	nn	_
16	and	and	CC	_	15	cc	_
17	commercialization	commercialization	NN	_	15	conj	_
18	agreement	agreement	NN	_	13	pobj	_
19	with	with	IN	_	18	prep	_
20	Ophthotech	ophthotech	NNP	_	21	nn	_
21	Corporation	corporation	NNP	_	19	pobj	_
22	(	(	-LRB-	_	23	punct	_
23	Ophthotech	ophthotech	NNP	_	21	appos	_
24	)	)	-RRB-	_	23	punct	_
25	for	for	IN	_	18	prep	_
26	the	the	DT	_	28	det	_
27	exclusive	exclusive	JJ	_	28	amod	_
28	rights	right	NNS	_	25	pobj	_
29	to	to	IN	p2=TO	28	prep	_
30	market	market	NN	_	31	nn	_
31	Fovista®	fovista®	NNP	p2=CD	29	pobj	_
32	(	(	-LRB-	_	34	punct	_
33	anti-PDGF	anti-pdgf	JJ	p2=NNP	34	amod	_
34	aptamer	aptamer	NN	p2=IN	31	parataxis	_
35	)	)	-RRB-	_	34	punct	_
36	outside	outside	IN	_	31	prep	_
37	the	the	DT	_	39	det	_
38	United	united	NNP	_	39	nn	_
39	States	states	NNP	_	36	pobj	_
40	.	.	.	_	9	punct	_

1	Under	under	IN	_	11	prep	11:AM-LOC
2	the	the	DT	_	4	det	_
3	financial	financial	JJ	_	4	amod	_
4	terms	term	NNS	_	1	pobj	_
5	of	of	IN	_	4	prep	_
6	the	the	DT	_	7	det	_
7	agreement	agreement	NN	_	5	pobj	_
8	,	,	,	_	11	punct	_
9	Ophthotech	ophthotech	NNP	_	11	nsubj	11:A0=PAG
10	will	will	MD	_	11	aux	11:AM-MOD
11	receive	receive	VB	pb=receive.01	0	root	_
12	an	an	DT	_	14	det	_
13	immediate	immediate	JJ	_	14	amod	_
14	payment	payment	NN	_	11	dobj	11:A1=PPT
15	of	of	IN	_	14	prep	_
16	an	an	DT	_	18	det	_
17	upfront	upfront	JJ	_	18	amod	_
18	fee	fee	NN	_	15	pobj	_
19	of	of	IN	_	18	prep	_
20	USD	usd	$	p2=NN	22	quantmod	_
21	200	0	CD	_	22	number	_
22	million	#crd#	CD	_	19	pobj	_
23	plus	plus	CC	p2=IN	22	nmod	_
24	potential	potential	JJ	_	26	amod	_
25	future	future	JJ	p2=NN	26	amod	_
26	recruitment	recruitment	NN	_	22	appos	_
27	and	and	CC	_	26	cc	_
28	other	other	JJ	_	30	amod	_
29	milestone	milestone	NN	_	30	nn	_
30	payments	payment	NNS	_	26	conj	_
31	.	.	.	_	11	punct	_

1	In	in	IN	_	5	prep	5:AM-DIS
2	addition	addition	NN	_	1	pobj	_
3	,	,	,	_	5	punct	_
4	Ophthotech	ophthotech	NNP	_	5	nsubj	8:A0=PAG;5:A1=PPT
5	is	be	VBZ	pb=be.01	0	root	_
6	eligible	eligible	JJ	_	5	acomp	5:A2=PRD
7	to	to	TO	_	8	aux	_
8	receive	receive	VB	pb=receive.01	6	xcomp	_
9	royalties	royalty	NNS	_	8	dobj	8:A1=PPT
10	on	on	IN	p2=RP	8	prep	_
11	ex-US	ex-us	NNS	p2=JJ	10	pobj	_
12	Fovista®	fovista®	IN	p2=POS	11	prep	_
13	sales	sale	NNS	_	12	pobj	_
14	.	.	.	_	5	punct	_

1	Fovista	fovista	NNP	p2=NN	4	nsubjpass	4:A1=PPT
2	is	be	VBZ	_	4	aux	_
3	being	be	VBG	_	4	auxpass	_
4	studied	study	VBN	pb=study.01	0	root	_
5	in	in	IN	_	4	prep	4:AM-LOC
6	combination	combination	NN	_	5	pobj	_
7	with	with	IN	_	6	prep	_
8	anti-VEGF	anti-vegf	JJ	_	9	amod	_
9	agents	agent	NNS	_	7	pobj	_
10	for	for	IN	_	9	prep	_
11	patients	patient	NNS	_	10	pobj	12:A0=PPT
12	suffering	suffer	VBG	pb=suffer.01	11	partmod	_
13	from	from	IN	_	12	prep	12:A1=PAG
14	wet	wet	JJ	_	19	amod	_
15	age	age	NN	_	17	hmod	_
16	-	-	HYPH	_	17	hyph	_
17	related	relate	VBN	_	19	amod	_
18	macular	macular	JJ	_	19	amod	_
19	degeneration	degeneration	NN	_	13	pobj	_
20	(	(	-LRB-	_	19	punct	_
21	wet	wet	JJ	p2=NN	22	amod	_
22	AMD	amd	NNP	p2=NN	19	appos	_
23	)	)	-RRB-	_	19	punct	_
24	.	.	.	_	4	punct	_

1	Novartis	novartis	NNP	p2=NNS	4	nsubj	4:A0=PAG
2	will	will	MD	_	4	aux	4:AM-MOD
3	also	also	RB	_	4	advmod	4:AM-DIS
4	develop	develop	VB	pb=develop.02	0	root	_
5	a	a	DT	_	6	det	_
6	co-formulation	co-formulation	NN	_	4	dobj	4:A1=PRD
7	of	of	IN	_	6	prep	_
8	Fovista	fovista	NNP	p2=NN	7	pobj	_
9	with	with	IN	_	4	prep	4:AM-MNR
10	a	a	DT	_	14	det	_
11	Novartis	novartis	NNP	p2=RB	14	nn	_
12	proprietary	proprietary	JJ	p2=NN	14	amod	_
13	anti-VEGF	anti-vegf	JJ	p2=NN	14	amod	_
14	treatment	treatment	NN	_	9	pobj	_
15	.	.	.	_	4	punct	_

1	Ophthotech	ophthotech	NNP	p2=NN	3	nsubj	3:A0=PAG
2	will	will	MD	_	3	aux	3:AM-MOD
3	hold	hold	VB	pb=hold.01	0	root	_
4	the	the	DT	_	6	det	_
5	marketing	marketing	NN	_	6	nn	_
6	rights	right	NNS	_	3	dobj	3:A1=PPT
7	to	to	IN	p2=TO	6	prep	_
8	Fovista	fovista	NNP	p2=NN	7	pobj	_
9	in	in	IN	_	8	prep	_
10	the	the	DT	_	12	det	_
11	United	united	NNP	_	12	nn	_
12	States	states	NNP	_	9	pobj	_
13	.	.	.	_	3	punct	_

1	"	"	``	p2=''	4	punct	_
2	Novartis	novartis	NNP	p2=NNPS	4	nsubjpass	6:A0=PAG;4:A1=PPT
3	is	be	VBZ	pb=be.01	0	root	_
4	committed	commit	VBN	p2=JJ|pb=commit.01	3	acomp	3:A2=PRD
5	to	to	IN	_	4	prep	4:A2=GOL
6	addressing	address	VBG	pb=address.02	5	pcomp	_
7	key	key	JJ	p2=NN	9	amod	_
8	unmet	unmet	JJ	p2=NN	9	amod	_
9	needs	need	NNS	_	6	dobj	6:A1=PPT
10	in	in	IN	_	6	prep	6:AM-MNR
11	medical	medical	JJ	_	12	amod	_
12	retina	retina	NN	p2=NNS	10	pobj	_
13	.	.	.	_	3	punct	_

1	Fovista	fovista	NNS	p2=NNP	11	nsubj	11:A0=PAG
2	in	in	IN	_	1	prep	_
3	combination	combination	NN	_	2	pobj	_
4	with	with	IN	_	3	prep	_
5	currently	currently	RB	_	6	advmod	_
6	available	available	JJ	_	8	amod	_
7	anti-VEGF	anti-vegf	JJ	p2=IN	8	amod	_
8	treatments	treatment	NNS	_	4	pobj	_
9	could	could	MD	_	11	aux	11:AM-MOD
10	further	far	RB	_	11	advmod	11:AM-EXT
11	improve	improve	VB	pb=improve.01	22	ccomp	22:A1=PPT
12	outcomes	outcome	NNS	_	11	dobj	11:A1=PPT
13	of	of	IN	_	12	prep	_
14	patients	patient	NNS	_	13	pobj	15:A0=PPT
15	suffering	suffer	VBG	pb=suffer.01	14	partmod	_
16	from	from	IN	_	15	prep	15:A1=PAG
17	avoidable	avoidable	JJ	_	19	amod	_
18	vision	vision	NN	_	19	nn	_
19	loss	loss	NN	_	16	pobj	_
20	,	,	,	_	22	punct	_
21	"	"	''	_	22	punct	_
22	said	say	VBD	pb=say.01	0	root	_
23	David	david	NNP	_	24	nn	_
24	Epstein	epstein	NNP	_	22	nsubj	22:A0
25	,	,	,	_	24	punct	_
26	Division	division	NNP	_	27	nn	_
27	Head	head	NNP	_	24	appos	_
28	,	,	,	_	27	punct	_
29	Novartis	novartis	NNP	_	30	nn	_
30	Pharmaceuticals	pharmaceutical	NNPS	p2=NNP	27	conj	_
31	.	.	.	_	22	punct	_

1	"	"	``	_	7	punct	_
2	If	if	IN	_	3	mark	_
3	approved	approve	VBN	pb=approve.01	7	advcl	7:AM-ADV
4	,	,	,	_	7	punct	_
5	Fovista	fovista	NNP	_	7	nsubjpass	7:A1=PPT;9:A1=PPT
6	is	be	VBZ	_	7	auxpass	_
7	expected	expect	VBN	pb=expect.01	0	root	_
8	to	to	TO	_	9	aux	_
9	be	be	VB	pb=be.01	7	xcomp	7:C-A1
10	the	the	DT	_	11	det	_
11	first	#ord#	JJ	_	9	attr	13:A0=PAG;9:A2=PRD
12	to	to	TO	p2=IN	13	aux	_
13	market	market	VB	p2=NN|pb=market.01	11	infmod	_
14	in	in	IN	_	13	prep	13:AM-LOC
15	this	this	DT	_	16	det	_
16	class	class	NN	_	14	pobj	_
17	of	of	IN	_	16	prep	_
18	therapies	therapy	NNS	_	17	pobj	_
19	for	for	IN	_	13	prep	13:A3=PRD
20	wet	wet	JJ	p2=NN	21	amod	_
21	AMD	amd	NNP	p2=NN	19	pobj	22:A0=PAG
22	confirming	confirm	VBG	pb=confirm.01	21	partmod	_
23	our	our	PRP$	_	24	poss	_
24	commitment	commitment	NN	_	22	dobj	22:A1=PPT
25	and	and	CC	_	24	cc	_
26	leadership	leadership	NN	_	24	conj	_
27	in	in	IN	_	24	prep	_
28	the	the	DT	_	30	det	_
29	ophthalmology	ophthalmology	NN	p2=JJ	30	nn	_
30	space	space	NN	_	27	pobj	_
31	.	.	.	_	7	punct	_
32	"	"	''	_	7	punct	_

1	Fovista	fovista	NNP	p2=PRP	2	nsubj	2:A0=PAG
2	offers	offer	VBZ	pb=offer.01	0	root	_
3	a	a	DT	_	5	det	_
4	new	new	JJ	_	5	amod	_
5	mechanism	mechanism	NN	_	2	dobj	2:A1=PPT
6	of	of	IN	_	5	prep	_
7	action	action	NN	_	6	pobj	_
8	to	to	TO	p2=IN	9	aux	_
9	address	address	VB	p2=NN|pb=address.02	7	infmod	_
10	unmet	unmet	PRP	p2=JJ	9	dobj	9:A1=PPT
11	need	need	VB	p2=VBP|pb=need.01	9	dep	_
12	to	to	TO	_	14	aux	_
13	further	far	RB	_	14	advmod	14:AM-EXT
14	improve	improve	VB	pb=improve.01	11	xcomp	11:A1=PPT
15	visual	visual	JJ	_	16	amod	_
16	acuity	acuity	NN	_	14	dobj	14:A1=PPT
17	and	and	CC	_	14	cc	_
18	potentially	potentially	RB	_	19	advmod	_
19	slow	slow	JJ	_	21	amod	_
20	disease	disease	NN	_	21	nn	_
21	progression	progression	NN	_	14	conj	_
22	.	.	.	_	2	punct	_

1	In	in	IN	_	17	prep	17:AM-LOC
2	Phase	phase	NNP	p2=NN	3	nn	_
3	II	ii	NNP	_	5	nn	_
4	clinical	clinical	JJ	_	5	amod	_
5	studies	study	NNS	_	1	pobj	_
6	,	,	,	_	17	punct	_
7	combination	combination	NN	_	8	nn	_
8	therapy	therapy	NN	_	17	nsubj	17:A0=PAG
9	of	of	IN	_	8	prep	_
10	Fovista	fovista	NNP	p2=NN	9	pobj	_
11	and	and	CC	_	10	cc	_
12	Lucentis®	lucentis®	NNP	_	10	conj	_
13	(	(	-LRB-	_	14	punct	_
14	ranibizumab	ranibizumab	NNP	p2=NN	10	appos	_
15	)	)	-RRB-	_	14	punct	_
16	significantly	significantly	RB	_	17	advmod	17:AM-MNR
17	improved	improve	VBD	p2=VBN|pb=improve.01	0	root	_
18	baseline	baseline	NN	p2=RB	20	nn	_
19	visual	visual	JJ	_	20	amod	_
20	acuity	acuity	NN	_	17	dobj	17:A1=PPT
21	in	in	IN	_	17	prep	_
22	wet	wet	JJ	_	24	amod	_
23	AMD	amd	NNP	p2=NN	24	nn	_
24	patients	patient	NNS	_	21	pobj	_
25	.	.	.	_	17	punct	_

1	No	no	DT	p2=UH	4	det	_
2	new	new	JJ	_	4	amod	_
3	safety	safety	NN	_	4	nn	_
4	signals	signal	NNS	_	6	nsubjpass	6:A1=PAG
5	were	be	VBD	_	6	auxpass	_
6	observed	observe	VBN	p2=JJ|pb=observe.01	0	root	_
7	with	with	IN	_	6	prep	6:AM-MNR
8	Fovista	fovista	NNP	_	10	nn	_
9	/	/	SYM	_	10	punct	_
10	Lucentis	lucentis	NNP	p2=NNPS	12	nn	_
11	adjunctive	adjunctive	NN	p2=JJ	12	nn	_
12	therapy	therapy	NN	_	7	pobj	_
13	as	as	IN	_	6	prep	_
14	compared	compare	VBN	_	13	prep	_
15	to	to	IN	p2=TO	14	prep	_
16	Lucentis	lucentis	NNP	p2=NNPS	17	nn	_
17	monotherapy	monotherapy	NN	p2=NNP	15	pobj	_
18	.	.	.	_	6	punct	_

1	Novartis	novartis	NNP	p2=RB	2	nsubj	2:A0;4:A0=PAG
2	expects	expect	VBZ	pb=expect.01	0	root	_
3	to	to	TO	_	4	aux	_
4	develop	develop	VB	pb=develop.02	2	xcomp	2:A1=PPT
5	Fovista	fovista	NNP	p2=NNS	4	dobj	4:A1=PRD
6	and	and	CC	_	5	cc	_
7	the	the	DT	_	8	det	_
8	co-formulation	co-formulation	NN	_	5	conj	_
9	in	in	IN	_	8	prep	_
10	its	its	PRP$	_	15	poss	_
11	proprietary	proprietary	JJ	_	15	amod	_
12	,	,	,	_	11	punct	_
13	innovative	innovative	JJ	_	15	amod	_
14	pre-filled	pre-filled	JJ	p2=VBN	15	amod	_
15	syringe	syringe	NN	_	9	pobj	_
16	as	as	IN	_	15	prep	_
17	part	part	NN	_	16	pobj	_
18	of	of	IN	_	17	prep	_
19	this	this	DT	_	20	det	_
20	agreement	agreement	NN	_	18	pobj	_
21	.	.	.	_	2	punct	_

1	Novartis	novartis	NNP	p2=UH	10	nsubj	10:A1=PPT
2	,	,	,	_	10	punct	_
3	through	through	IN	_	10	prep	_
4	its	its	PRP$	_	5	poss	_
5	Alcon	alcon	NNP	p2=NN	10	nsubj	_
6	and	and	CC	_	5	cc	_
7	Pharmaceuticals	pharmaceuticals	NNP	p2=NNPS	8	nn	_
8	Divisions	divisions	NNP	p2=NNS	5	conj	_
9	,	,	,	_	10	punct	_
10	is	be	VBZ	pb=be.01	0	root	_
11	the	the	DT	_	13	det	_
12	global	global	JJ	_	13	amod	_
13	leader	leader	NN	_	10	attr	10:A2=PRD
14	and	and	CC	_	13	cc	_
15	partner	partner	NN	_	13	conj	_
16	for	for	IN	_	15	prep	_
17	physicians	physician	NNS	_	16	pobj	_
18	in	in	IN	_	17	prep	_
19	medical	medical	JJ	_	20	amod	_
20	retina	retina	NN	p2=NNS	18	pobj	_
21	,	,	,	_	10	punct	_
22	and	and	CC	_	10	cc	_
23	as	as	RB	p2=IN	24	advmod	_
24	such	such	JJ	_	26	amod	_
25	,	,	,	_	26	punct	_
26	offers	offer	VBZ	pb=offer.01	10	conj	_
27	the	the	DT	_	28	det	_
28	industry	industry	NN	_	26	dobj	26:A1=PPT
29	`	`	``	_	30	punct	_
30	s	s	VBZ	p2=VBD	26	ccomp	_
31	most	most	RBS	p2=JJS	32	advmod	_
32	comprehensive	comprehensive	JJ	_	33	amod	_
33	portfolio	portfolio	NN	_	30	dobj	_
34	of	of	IN	_	33	prep	_
35	innovative	innovative	JJ	_	37	amod	_
36	retina	retina	JJ	p2=NN	37	amod	_
37	products	product	NNS	_	34	pobj	_
38	to	to	TO	p2=IN	39	aux	_
39	support	support	VB	pb=support.01	37	infmod	_
40	professionals	professional	NNS	_	39	dobj	42:A0=PAG;39:A1
41	to	to	TO	_	42	aux	_
42	help	help	VB	pb=help.01	39	advcl	_
43	achieve	achieve	VB	pb=achieve.01	42	xcomp	42:A1=PPT
44	the	the	DT	_	48	det	_
45	best	good	JJS	p2=RBS	46	advmod	_
46	possible	possible	JJ	_	48	amod	_
47	patient	patient	JJ	p2=NN	48	amod	_
48	outcomes	outcome	NNS	_	43	dobj	43:A1=PPT
49	.	.	.	_	26	punct	_

1	Novartis	novartis	NNP	p2=RB	4	nn	_
2	medical	medical	JJ	_	3	amod	_
3	retina	retina	NN	p2=JJ	4	nn	_
4	pipeline	pipeline	NN	_	5	nsubj	5:A2=GOL
5	includes	include	VBZ	pb=include.01	0	root	_
6	investigational	investigational	JJ	p2=IN	7	amod	_
7	treatments	treatment	NNS	_	5	dobj	5:A1=PPT
8	in	in	IN	_	7	prep	_
9	late	late	JJ	_	11	hmod	_
10	-	-	HYPH	_	11	hyph	_
11	stage	stage	NN	_	13	nn	_
12	clinical	clinical	JJ	_	13	amod	_
13	development	development	NN	_	8	pobj	_
14	such	such	JJ	_	15	amod	_
15	as	as	IN	_	13	prep	_
16	RTH258	rth258	NNP	p2=NNS	15	pobj	_
17	for	for	IN	_	16	prep	_
18	wet	wet	JJ	_	19	amod	_
19	AMD	amd	NNP	_	17	pobj	_
20	(	(	-LRB-	_	23	punct	_
21	next	next	JJ	p2=RB	22	amod	_
22	generation	generation	NN	_	23	nsubj	_
23	anti-VEGF	anti-vegf	JJ	p2=NNP	19	appos	_
24	)	)	-RRB-	_	23	punct	_
25	,	,	,	_	5	punct	_
26	and	and	CC	_	5	cc	_
27	LFG316	lfg316	NNP	p2=CD	5	conj	_
28	for	for	IN	_	27	prep	_
29	the	the	DT	_	30	det	_
30	treatment	treatment	NN	_	28	pobj	_
31	of	of	IN	_	30	prep	_
32	dry	dry	JJ	_	33	amod	_
33	AMD	amd	NNP	p2=NN	31	pobj	_
34	.	.	.	_	5	punct	_

1	Novartis	novartis	NNP	p2=NN	2	nsubj	2:A0=PAG
2	holds	hold	VBZ	pb=hold.01	0	root	_
3	the	the	DT	_	5	det	_
4	marketing	marketing	NN	_	5	nn	_
5	rights	right	NNS	_	2	dobj	2:A1=PPT
6	for	for	IN	_	5	prep	_
7	Fovista	fovista	NNP	p2=NN	6	pobj	_
8	(	(	-LRB-	_	10	punct	_
9	anti-PDGF	anti-pdgf	JJ	p2=NNP	10	amod	_
10	aptamer	aptamer	NN	p2=IN	7	parataxis	_
11	)	)	-RRB-	_	10	punct	_
12	outside	outside	IN	_	7	prep	_
13	the	the	DT	_	15	det	_
14	United	united	NNP	_	15	nn	_
15	States	states	NNP	_	12	pobj	_
16	.	.	.	_	2	punct	_

1	Ophthotech	ophthotech	NNP	_	2	nn	_
2	Corporation	corporation	NNP	_	3	nsubj	3:A0=PAG
3	holds	hold	VBZ	pb=hold.01	0	root	_
4	the	the	DT	_	6	det	_
5	marketing	marketing	NN	_	6	nn	_
6	rights	right	NNS	p2=VBZ	3	dobj	3:A1=PPT
7	to	to	IN	p2=TO	6	prep	_
8	Fovista	fovista	NNP	p2=NN	7	pobj	_
9	in	in	IN	_	8	prep	_
10	the	the	DT	_	12	det	_
11	United	united	NNP	_	12	nn	_
12	States	states	NNP	_	9	pobj	_
13	.	.	.	_	3	punct	_

1	Lucentis	lucentis	NNP	p2=NN	3	nsubjpass	5:A0=PAG;9:A0;3:A1=PRD
2	was	be	VBD	_	3	auxpass	_
3	designed	design	VBN	pb=design.01	0	root	_
4	to	to	TO	_	5	aux	_
5	save	save	VB	pb=save.01	3	xcomp	3:A3=PRP
6	sight	sight	NN	_	5	dobj	5:A1=PPT
7	and	and	CC	_	3	cc	_
8	has	have	VBZ	_	9	aux	_
9	demonstrated	demonstrate	VBN	p2=VBD|pb=demonstrate.01	3	conj	_
10	transformational	transformational	JJ	p2=FW	11	amod	_
11	efficacy	efficacy	NN	_	9	dobj	9:A1=PPT
12	with	with	IN	_	9	prep	9:AM-MNR
13	individualized	individualized	JJ	p2=VBN	12	pobj	14:A1=PPT
14	dosing	dose	VBG	p2=NN|pb=dose.01	13	partmod	_
15	in	in	IN	_	14	prep	14:AM-LOC
16	its	its	PRP$	_	18	poss	_
17	licensed	licensed	JJ	p2=VBN	18	amod	_
18	indications	indication	NNS	_	15	pobj	_
19	.	.	.	_	3	punct	_

1	As	as	IN	_	16	prep	16:AM-PRD
2	an	an	DT	_	4	det	_
3	antibody	antibody	NN	_	4	nn	_
4	fragment	fragment	NN	_	1	pobj	_
5	with	with	IN	_	4	prep	_
6	a	a	DT	_	11	det	_
7	short	short	JJ	_	11	amod	_
8	systemic	systemic	JJ	p2=NN	11	amod	_
9	half	half	JJ	p2=NN	11	hmod	_
10	-	-	HYPH	_	11	hyph	_
11	life	life	NN	_	5	pobj	_
12	,	,	,	_	16	punct	_
13	Lucentis	lucentis	NNP	_	16	nsubjpass	20:A0=PAG;16:A1=PRD;18:A1=PRD;22:A1=PPT
14	was	be	VBD	_	16	auxpass	_
15	specifically	specifically	RB	_	16	advmod	16:AM-MNR
16	designed	design	VBN	pb=design.01	0	root	_
17	,	,	,	_	16	punct	_
18	developed	develop	VBN	p2=VBD|pb=develop.02	16	conj	_
19	,	,	,	_	18	punct	_
20	formulated	formulate	VBN	pb=formulate.01	18	conj	_
21	and	and	CC	_	20	cc	_
22	licensed	license	VBN	pb=license.01	20	conj	_
23	for	for	IN	_	22	prep	22:A2=GOL
24	ocular	ocular	JJ	p2=NN	25	amod	_
25	conditions	condition	NNS	_	23	pobj	_
26	,	,	,	_	20	punct	_
27	and	and	CC	_	20	cc	_
28	is	be	VBZ	_	29	auxpass	_
29	manufactured	manufacture	VBN	pb=manufacture.01	20	conj	_
30	to	to	IN	_	29	prep	_
31	the	the	DT	_	33	det	_
32	highest	high	JJS	_	33	amod	_
33	standards	standard	NNS	_	30	pobj	_
34	for	for	IN	_	33	prep	_
35	intra-ocular	intra-ocular	JJ	_	36	amod	_
36	use	use	NN	_	34	pobj	_
37	.	.	.	_	16	punct	_

1	Lucentis	lucentis	NNP	p2=NN	3	nsubjpass	3:A1=PPT
2	is	be	VBZ	_	3	auxpass	_
3	licensed	license	VBN	p2=JJ|pb=license.01	0	root	_
4	in	in	IN	_	3	prep	3:AM-LOC
5	more	more	JJR	p2=RBR	7	amod	_
6	than	than	IN	_	7	quantmod	_
7	100	0	CD	_	8	num	_
8	countries	country	NNS	_	4	pobj	_
9	,	,	,	_	3	punct	_
10	for	for	IN	_	3	prep	3:AM-PNC
11	the	the	DT	_	12	det	_
12	treatment	treatment	NN	_	10	pobj	_
13	of	of	IN	_	12	prep	_
14	wet	wet	JJ	_	19	amod	_
15	age	age	NN	_	17	hmod	_
16	-	-	HYPH	_	17	hyph	_
17	related	relate	VBN	_	19	amod	_
18	macular	macular	JJ	_	19	amod	_
19	degeneration	degeneration	NN	_	13	pobj	_
20	(	(	-LRB-	_	19	punct	_
21	wet	wet	JJ	p2=NN	22	amod	_
22	AMD	amd	NNP	_	19	appos	_
23	)	)	-RRB-	_	19	punct	_
24	,	,	,	_	26	punct	_
25	visual	visual	JJ	_	26	amod	_
26	impairment	impairment	NN	_	19	appos	_
27	due	due	IN	p2=JJ	26	prep	_
28	to	to	IN	_	27	pcomp	_
29	diabetic	diabetic	JJ	_	31	amod	_
30	macular	macular	JJ	p2=NN	31	amod	_
31	edema	edema	NN	p2=NNS	27	pobj	_
32	(	(	-LRB-	_	31	punct	_
33	DME	dme	NNP	_	31	appos	_
34	)	)	-RRB-	_	31	punct	_
35	and	and	CC	_	27	cc	_
36	for	for	IN	_	27	conj	_
37	visual	visual	JJ	_	38	amod	_
38	impairment	impairment	NN	_	36	pobj	_
39	due	due	IN	p2=JJ	38	prep	_
40	to	to	IN	p2=TO	39	pcomp	_
41	macular	macular	JJ	p2=FW	42	amod	_
42	edema	edema	NN	p2=NNS	39	pobj	_
43	secondary	secondary	JJ	_	42	amod	_
44	to	to	IN	p2=TO	43	prep	_
45	retinal	retinal	JJ	p2=NN	46	amod	_
46	vein	vein	NN	_	47	nn	_
47	occlusion	occlusion	NN	p2=NNP	44	pobj	_
48	(	(	-LRB-	_	49	punct	_
49	RVO	rvo	NNP	_	47	appos	_
50	)	)	-RRB-	_	49	punct	_
51	,	,	,	_	47	punct	_
52	including	include	VBG	_	42	prep	_
53	both	both	DT	p2=CC	59	det	_
54	branch	branch	NN	_	59	hmod	_
55	-	-	HYPH	p2=:	54	hyph	_
56	and	and	CC	_	54	cc	_
57	central	central	JJ	p2=NN	54	conj	_
58	-	-	HYPH	_	59	hyph	_
59	RVO	rvo	NNP	p2=NN	52	pobj	_
60	.	.	.	_	3	punct	_

1	Also	also	RB	_	5	advmod	5:AM-DIS
2	,	,	,	_	5	punct	_
3	Lucentis	lucentis	NNP	_	5	nsubjpass	5:A1=PPT
4	is	be	VBZ	_	5	auxpass	_
5	licensed	license	VBN	p2=JJ|pb=license.01	0	root	_
6	in	in	IN	_	5	prep	5:AM-LOC
7	more	more	JJR	p2=RBR	9	amod	_
8	than	than	IN	_	9	quantmod	_
9	60	0	CD	_	10	num	_
10	countries	country	NNS	_	6	pobj	_
11	,	,	,	_	5	punct	_
12	not	not	RB	_	13	neg	_
13	including	include	VBG	_	10	prep	_
14	the	the	DT	_	15	det	_
15	US	us	NNP	_	13	pobj	_
16	,	,	,	_	10	punct	_
17	for	for	IN	_	15	prep	_
18	the	the	DT	_	19	det	_
19	treatment	treatment	NN	_	17	pobj	_
20	of	of	IN	_	19	prep	_
21	patients	patient	NNS	_	20	pobj	_
22	with	with	IN	_	21	prep	_
23	visual	visual	JJ	_	24	amod	_
24	impairment	impairment	NN	_	22	pobj	_
25	due	due	IN	p2=JJ	19	prep	_
26	to	to	IN	p2=TO	25	pcomp	_
27	choroidal	choroidal	JJ	p2=NN	28	amod	_
28	neovascularization	neovascularization	NN	_	25	pobj	_
29	(	(	-LRB-	_	28	punct	_
30	CNV	cnv	NNP	p2=NN	28	appos	_
31	)	)	-RRB-	_	28	punct	_
32	secondary	secondary	JJ	_	28	amod	_
33	to	to	TO	p2=IN	34	aux	_
34	pathologic	pathologic	VB	p2=JJ|pb=pathologic.01	32	xcomp	_
35	myopia	myopia	NN	p2=FW	34	dobj	34:A1
36	(	(	-LRB-	_	35	punct	_
37	myopic	myopic	JJ	p2=NN	38	nn	_
38	CNV	cnv	NNP	p2=NN	35	appos	_
39	)	)	-RRB-	_	35	punct	_
40	.	.	.	_	5	punct	_

1	In	in	IN	_	11	prep	11:AM-LOC
2	most	most	JJS	_	3	amod	_
3	countries	country	NNS	_	1	pobj	_
4	,	,	,	_	11	punct	_
5	including	include	VBG	_	11	prep	11:AM-ADV
6	those	those	DT	_	5	pobj	_
7	in	in	IN	_	6	prep	_
8	Europe	europe	NNP	_	7	pobj	_
9	,	,	,	_	11	punct	_
10	Lucentis	lucentis	NNP	_	11	nsubj	11:A0=PAG
11	has	have	VBZ	pb=have.03	0	root	_
12	an	an	DT	_	15	det	_
13	individualized	individualized	JJ	_	15	amod	_
14	treatment	treatment	NN	_	15	nn	_
15	regimen	regimen	NNS	p2=NN	11	dobj	11:A1=PPT
16	with	with	IN	_	15	prep	_
17	the	the	DT	_	18	det	_
18	goal	goal	NN	_	16	pobj	_
19	of	of	IN	_	18	prep	_
20	maximizing	maximize	VBG	pb=maximize.01	19	pcomp	_
21	visual	visual	JJ	_	22	amod	_
22	outcomes	outcome	NNS	_	20	dobj	20:A1=PPT
23	while	while	IN	_	24	mark	_
24	minimizing	minimize	VBG	pb=minimize.01	20	advcl	20:AM-TMP
25	under	under	IN	p2=NN	27	hmod	_
26	-	-	HYPH	p2=,	27	hyph	_
27	or	or	CC	_	29	cc	_
28	over-treating	over-treating	JJ	p2=VBG	29	amod	_
29	patients	patient	NNS	_	24	dobj	24:A1=PPT
30	.	.	.	_	11	punct	_

1	Lucentis	lucentis	NNP	p2=NNPS	2	nsubj	2:A0=PAG
2	has	have	VBZ	pb=have.03	0	root	_
3	a	a	DT	_	8	det	_
4	well	well	RB	_	6	hmod	_
5	-	-	HYPH	_	6	hyph	_
6	established	establish	VBN	_	8	amod	_
7	safety	safety	NN	_	8	nn	_
8	profile	profile	NN	_	2	dobj	2:A1=PPT;9:A1
9	supported	support	VBN	pb=support.01	8	partmod	_
10	by	by	IN	_	9	agent	9:A0
11	43	0	CD	_	14	num	_
12	sponsored	sponsor	VBN	pb=sponsor.01	14	amod	_
13	clinical	clinical	JJ	_	14	amod	_
14	studies	study	NNS	_	10	pobj	12:A1=GOL
15	and	and	CC	_	14	cc	_
16	real	real	JJ	_	18	hmod	_
17	-	-	HYPH	_	18	hyph	_
18	world	world	NN	_	19	nn	_
19	experience	experience	NN	_	14	conj	_
20	.	.	.	_	2	punct	_

1	Its	its	PRP$	_	3	poss	_
2	safety	safety	NN	_	3	nn	_
3	profile	profile	NN	_	7	nsubjpass	7:A1=PPT
4	has	have	VBZ	_	7	aux	_
5	been	be	VBN	_	7	auxpass	_
6	well	well	RB	_	7	advmod	7:AM-MNR
7	established	establish	VBN	pb=establish.01	0	root	_
8	in	in	IN	_	7	prep	7:AM-LOC
9	a	a	DT	_	12	det	_
10	clinical	clinical	JJ	_	12	amod	_
11	development	development	NN	_	12	nn	_
12	program	program	NN	_	8	pobj	14:A0
13	that	that	WDT	_	14	nsubj	14:R-A0
14	enrolled	enrol	VBD	pb=enroll.01	12	rcmod	_
15	more	more	JJR	_	17	amod	_
16	than	than	IN	_	17	quantmod	_
17	12,500	0	CD	_	18	num	_
18	patients	patient	NNS	_	14	dobj	14:A1
19	across	across	IN	_	14	prep	14:A2
20	indications	indication	NNS	_	19	pobj	_
21	and	and	CC	_	14	cc	_
22	there	there	EX	_	23	expl	_
23	is	be	VBZ	pb=be.02	14	conj	_
24	more	more	JJR	_	27	amod	_
25	than	than	IN	_	27	quantmod	_
26	2.4	0	CD	_	27	number	_
27	million	#crd#	CD	_	31	num	_
28	patient	patient	JJ	p2=NN	30	hmod	_
29	-	-	HYPH	_	30	hyph	_
30	treatment	treatment	NN	_	31	nn	_
31	years	year	NNS	_	23	attr	23:A1=PPT
32	of	of	IN	_	31	prep	_
33	exposure	exposure	NN	_	32	pobj	_
34	since	since	IN	_	33	prep	_
35	its	its	PRP$	_	36	poss	_
36	launch	launch	NN	_	34	pobj	_
37	in	in	IN	_	36	prep	_
38	the	the	DT	_	40	det	_
39	United	united	NNP	_	40	nn	_
40	States	states	NNP	p2=NNPS	37	pobj	_
41	in	in	IN	_	36	prep	_
42	2006	0	CD	_	41	pobj	_
43	.	.	.	_	7	punct	_

1	Lucentis	lucentis	NNP	p2=NN	3	nsubjpass	3:A1=PRD
2	was	be	VBD	_	3	auxpass	_
3	developed	develop	VBN	pb=develop.02	0	root	_
4	by	by	IN	_	3	agent	3:A0=PAG
5	Genentech	genentech	NNP	_	4	pobj	_
6	and	and	CC	_	5	cc	_
7	Novartis	novartis	NNP	_	5	conj	_
8	.	.	.	_	3	punct	_

1	Genentech	genentech	NNP	p2=NN	2	nsubj	2:A0=PAG
2	has	have	VBZ	pb=have.03	0	root	_
3	the	the	DT	_	5	det	_
4	commercial	commercial	JJ	_	5	amod	_
5	rights	right	NNS	_	2	dobj	2:A1=PPT
6	to	to	IN	p2=TO	5	prep	_
7	Lucentis	lucentis	NNP	p2=NNPS	6	pobj	_
8	in	in	IN	_	7	prep	_
9	the	the	DT	_	11	det	_
10	United	united	NNP	_	11	nn	_
11	States	states	NNP	_	8	pobj	_
12	.	.	.	_	2	punct	_

1	Novartis	novartis	NNP	p2=RB	2	nsubj	2:A0=PAG
2	has	have	VBZ	pb=have.03	0	root	_
3	exclusive	exclusive	JJ	_	4	amod	_
4	rights	right	NNS	_	2	dobj	2:A1=PPT
5	in	in	IN	_	4	prep	_
6	the	the	DT	_	7	det	_
7	rest	rest	NN	_	5	pobj	_
8	of	of	IN	_	7	prep	_
9	the	the	DT	_	10	det	_
10	world	world	NN	_	8	pobj	_
11	.	.	.	_	2	punct	_

1	Lucentis	lucentis	NNP	p2=NNPS	2	nsubj	2:A1=PPT
2	is	be	VBZ	pb=be.01	0	root	_
3	a	a	DT	_	5	det	_
4	registered	register	VBN	p2=JJ|pb=register.02	5	amod	_
5	trademark	trademark	NN	_	2	attr	4:A1=PPT;2:A2=PRD
6	of	of	IN	_	5	prep	_
7	Genentech	genentech	NNP	_	8	nn	_
8	Inc	inc	NNP	_	6	pobj	_
9	.	.	.	_	2	punct	_

1	The	the	DT	_	3	det	_
2	foregoing	foregoing	JJ	p2=VBG	3	amod	_
3	release	release	NN	_	4	nsubj	4:A0
4	contains	contain	VBZ	pb=contain.01	0	root	_
5	forward	forward	RB	_	7	hmod	_
6	-	-	HYPH	_	7	hyph	_
7	looking	look	VBG	_	8	amod	_
8	statements	statement	NNS	_	4	dobj	4:A1;12:A1=PPT
9	that	that	WDT	_	12	nsubjpass	12:R-A1
10	can	can	MD	_	12	aux	12:AM-MOD
11	be	be	VB	_	12	auxpass	_
12	identified	identify	VBN	pb=identify.01	8	rcmod	_
13	by	by	IN	_	12	agent	12:A0=PAG
14	words	word	NNS	_	13	pobj	_
15	such	such	JJ	_	16	amod	_
16	as	as	IN	_	14	prep	_
17	"	"	``	_	19	punct	_
18	to	to	TO	p2=IN	19	aux	_
19	extend	extend	VB	pb=extend.01	16	pcomp	_
20	,	,	,	_	19	punct	_
21	"	"	''	p2=``	33	punct	_
22	"	"	``	_	33	punct	_
23	to	to	TO	p2=IN	24	aux	_
24	receive	receive	VB	pb=receive.01	3	infmod	_
25	,	,	,	_	33	punct	_
26	"	"	''	_	33	punct	_
27	"	"	``	_	33	punct	_
28	if	if	IN	_	29	mark	_
29	approved	approve	VBN	pb=approve.01	33	advcl	33:AM-ADV
30	,	,	,	_	33	punct	_
31	"	"	''	_	33	punct	_
32	"	"	``	_	33	punct	_
33	expected	expect	VBD	p2=VBN|pb=expect.01	4	ccomp	_
34	,	,	,	_	33	punct	_
35	"	"	''	_	33	punct	_
36	"	"	``	_	38	punct	_
37	to	to	TO	_	38	aux	_
38	be	be	VB	pb=be.01	29	xcomp	29:A2=PRD
39	,	,	,	_	71	punct	_
40	"	"	''	p2=``	71	punct	_
41	"	"	``	_	71	punct	_
42	to	to	TO	p2=IN	43	aux	_
43	commercialize	commercialize	VB	pb=commercialize.01	71	csubj	_
44	,	,	,	_	71	punct	_
45	"	"	''	p2=``	51	punct	_
46	"	"	``	_	51	punct	_
47	will	will	MD	p2=NN	51	aux	51:AM-MOD
48	,	,	,	_	51	punct	_
49	"	"	''	_	51	punct	_
50	"	"	``	_	51	punct	_
51	committed	commit	VBN	p2=VBD|pb=commit.02	43	ccomp	_
52	,	,	,	_	59	punct	_
53	"	"	''	_	59	punct	_
54	"	"	``	_	59	punct	_
55	could	could	MD	_	59	aux	_
56	,	,	,	_	59	punct	_
57	"	"	''	_	59	punct	_
58	"	"	``	_	59	punct	_
59	commitment	commitment	NN	_	51	dobj	_
60	,	,	,	_	63	punct	_
61	"	"	''	_	63	punct	_
62	"	"	``	_	63	punct	_
63	offers	offer	VBZ	p2=NNS|pb=offer.01	71	parataxis	_
64	,	,	,	_	63	punct	_
65	"	"	''	_	71	punct	_
66	"	"	``	_	71	punct	_
67	potentially	potentially	RB	_	71	advmod	_
68	,	,	,	_	71	punct	_
69	"	"	''	_	71	punct	_
70	"	"	``	_	71	punct	_
71	expects	expect	VBZ	_	38	attr	38:A2=PRD
72	,	,	,	_	71	punct	_
73	"	"	''	_	76	punct	_
74	"	"	``	_	93	punct	_
75	to	to	TO	p2=IN	76	aux	_
76	develop	develop	VB	pb=develop.02	59	infmod	_
77	,	,	,	_	80	punct	_
78	"	"	''	p2=``	80	punct	_
79	"	"	``	_	80	punct	_
80	pipeline	pipeline	NN	_	93	nn	_
81	,	,	,	_	80	punct	_
82	"	"	''	_	84	punct	_
83	"	"	``	_	84	punct	_
84	investigational	investigational	JJ	p2=NN	80	amod	_
85	,	,	,	_	84	punct	_
86	"	"	''	_	88	punct	_
87	"	"	``	_	88	punct	_
88	designed	design	VBN	p2=VBD|pb=design.01	84	conj	_
89	to	to	TO	p2=IN	88	xcomp	88:A3=PRP
90	,	,	,	_	93	punct	_
91	"	"	''	p2=``	93	punct	_
92	"	"	``	_	93	punct	_
93	goal	goal	NN	_	76	dobj	76:A1=PRD
94	,	,	,	_	93	punct	_
95	"	"	''	_	93	punct	_
96	or	or	CC	_	93	cc	_
97	similar	similar	JJ	_	98	amod	_
98	terms	term	NNS	_	93	conj	_
99	,	,	,	_	93	punct	_
100	or	or	CC	_	93	cc	_
101	by	by	IN	p2=RB	93	conj	_
102	express	express	NN	p2=JJ	105	amod	_
103	or	or	CC	_	102	cc	_
104	implied	imply	VBN	p2=JJ|pb=imply.01	102	conj	_
105	discussions	discussion	NNS	_	101	pobj	104:A1=PPT
106	regarding	regard	VBG	_	105	prep	_
107	potential	potential	JJ	p2=NN	109	amod	_
108	marketing	marketing	NN	p2=VBG	109	nn	_
109	approvals	approval	NNS	_	106	pobj	_
110	for	for	IN	_	109	prep	_
111	Fovista	fovista	NNP	p2=NN	110	pobj	_
112	,	,	,	_	111	punct	_
113	RTH258	rth258	NNP	p2=NNPS	111	conj	_
114	,	,	,	_	113	punct	_
115	LFG316	lfg316	NNP	_	113	conj	_
116	or	or	CC	_	115	cc	_
117	other	other	JJ	_	119	amod	_
118	investigational	investigational	JJ	_	119	amod	_
119	treatments	treatment	NNS	_	115	conj	_
120	in	in	IN	_	119	prep	_
121	the	the	DT	_	125	det	_
122	Novartis	novartis	NNP	p2=NNPS	125	nn	_
123	medical	medical	JJ	_	124	amod	_
124	retina	retina	NN	p2=JJ	125	nn	_
125	pipeline	pipeline	NN	_	120	pobj	_
126	,	,	,	_	119	punct	_
127	potential	potential	JJ	_	129	amod	_
128	new	new	JJ	_	129	amod	_
129	indications	indication	NNS	_	119	conj	_
130	or	or	CC	_	129	cc	_
131	labeling	labeling	NN	p2=VBG	129	conj	_
132	for	for	IN	_	131	prep	_
133	Lucentis	lucentis	NNP	p2=NNPS	132	pobj	_
134	or	or	CC	_	133	cc	_
135	Lucentis	lucentis	NNP	p2=NNPS	133	conj	_
136	pre-filled	pre-filled	VBD	p2=JJ|pb=pre-filled.01	137	amod	_
137	syringe	syringe	NN	p2=NNP	129	conj	136:A1
138	,	,	,	_	137	punct	_
139	and	and	CC	_	137	cc	_
140	potential	potential	JJ	_	142	amod	_
141	future	future	JJ	p2=NN	142	amod	_
142	revenues	revenue	NNS	_	137	conj	_
143	from	from	IN	_	142	prep	_
144	such	such	JJ	_	145	amod	_
145	products	product	NNS	_	143	pobj	_
146	.	.	.	_	4	punct	_

1	You	you	PRP	_	4	nsubj	4:A0=PAG
2	should	should	MD	_	4	aux	4:AM-MOD
3	not	not	RB	_	4	neg	4:AM-NEG
4	place	place	VB	pb=place.01	0	root	_
5	undue	undue	JJ	_	6	amod	_
6	reliance	reliance	NN	_	4	dobj	4:A1=PPT
7	on	on	IN	_	6	prep	_
8	these	these	DT	_	9	det	_
9	statements	statement	NNS	_	7	pobj	_
10	.	.	.	_	4	punct	_

1	Such	such	JJ	p2=PDT	5	amod	_
2	forward	forward	RB	_	4	hmod	_
3	-	-	HYPH	_	4	hyph	_
4	looking	look	VBG	_	5	amod	_
5	statements	statement	NNS	_	7	nsubjpass	7:A1=PPT;21:A1=PPT
6	are	be	VBP	_	7	auxpass	_
7	based	base	VBN	pb=base.02	0	root	_
8	on	on	IN	_	7	prep	7:A2=DIR
9	the	the	DT	_	11	det	_
10	current	current	JJ	_	11	amod	_
11	beliefs	belief	NNS	_	8	pobj	_
12	and	and	CC	_	11	cc	_
13	expectations	expectation	NNS	_	11	conj	_
14	of	of	IN	_	11	prep	_
15	management	management	NN	_	14	pobj	_
16	regarding	regard	VBG	_	11	prep	_
17	future	future	JJ	p2=NN	18	amod	_
18	events	event	NNS	_	16	pobj	_
19	,	,	,	_	7	punct	_
20	and	and	CC	_	7	cc	_
21	are	be	VBP	pb=be.01	7	conj	_
22	subject	subject	JJ	_	21	acomp	21:A2=PRD
23	to	to	IN	_	22	prep	_
24	significant	significant	JJ	_	28	amod	_
25	known	know	VBN	p2=JJ|pb=know.01	28	amod	_
26	and	and	CC	_	25	cc	_
27	unknown	unknown	JJ	_	25	conj	_
28	risks	risk	NNS	_	23	pobj	25:A1=PPT
29	and	and	CC	_	28	cc	_
30	uncertainties	uncertainty	NNS	_	28	conj	_
31	.	.	.	_	7	punct	_

1	Should	should	MD	_	10	aux	10:AM-MOD
2	one	#crd#	CD	p2=PRP	10	nsubj	10:A1=PPT
3	or	or	CC	_	2	cc	_
4	more	more	JJR	_	2	conj	_
5	of	of	IN	_	2	prep	_
6	these	these	DT	_	7	det	_
7	risks	risk	NNS	_	5	pobj	_
8	or	or	CC	_	7	cc	_
9	uncertainties	uncertainty	NNS	_	7	conj	_
10	materialize	materialize	VBP	pb=materialize.01	0	root	_
11	,	,	,	_	10	punct	_
12	or	or	CC	_	10	cc	_
13	should	should	MD	_	14	aux	14:AM-MOD
14	underlying	underlie	VBG	p2=JJ|pb=underlie.01	15	amod	_
15	assumptions	assumption	NNS	_	16	nsubj	14:A0=PPT;16:A0
16	prove	prove	VB	pb=prove.01	10	conj	_
17	incorrect	incorrect	JJ	_	20	amod	_
18	,	,	,	_	20	punct	_
19	actual	actual	JJ	_	20	amod	_
20	results	result	NNS	_	22	nsubj	22:A1=PPT
21	may	may	MD	_	22	aux	22:AM-MOD
22	vary	vary	VB	pb=vary.01	16	ccomp	16:A1=PPT
23	materially	materially	RB	_	22	advmod	22:A2=EXT
24	from	from	IN	_	23	prep	_
25	those	those	DT	_	24	pobj	26:A1=PPT
26	set	set	VBN	p2=NN|pb=set.01	25	partmod	_
27	forth	forth	RB	p2=RP	26	advmod	26:A2=LOC
28	in	in	IN	_	26	prep	26:AM-LOC
29	the	the	DT	_	33	det	_
30	forward	forward	RB	_	32	hmod	_
31	-	-	HYPH	_	32	hyph	_
32	looking	look	VBG	_	33	amod	_
33	statements	statement	NNS	_	28	pobj	_
34	.	.	.	_	16	punct	_

1	There	there	EX	_	3	expl	_
2	can	can	MD	_	3	aux	3:AM-MOD
3	be	be	VB	pb=be.02	0	root	_
4	no	no	DT	_	5	det	_
5	guarantee	guarantee	NN	_	3	attr	3:A1=PPT
6	that	that	IN	p2=WDT	25	complm	_
7	Fovista	fovista	NNP	_	25	nsubjpass	25:A1=PPT;27:A1=PPT
8	,	,	,	_	7	punct	_
9	RTH258	rth258	NNP	p2=XX	7	conj	_
10	,	,	,	_	9	punct	_
11	LFG316	lfg316	NNP	_	9	conj	_
12	or	or	CC	_	11	cc	_
13	any	any	DT	_	16	det	_
14	other	other	JJ	_	16	amod	_
15	investigational	investigational	JJ	_	16	amod	_
16	treatment	treatment	NN	_	11	conj	_
17	in	in	IN	_	16	prep	_
18	the	the	DT	_	22	det	_
19	Novartis	novartis	NNP	p2=NNPS	22	nn	_
20	medical	medical	JJ	_	21	amod	_
21	retina	retina	NN	p2=JJ	22	nn	_
22	pipeline	pipeline	NN	_	17	pobj	_
23	will	will	MD	_	25	aux	25:AM-MOD;27:AM-MOD
24	be	be	VB	_	25	auxpass	_
25	submitted	submit	VBN	pb=submit.01	5	ccomp	_
26	or	or	CC	_	25	cc	_
27	approved	approve	VBN	pb=approve.01	25	conj	_
28	for	for	IN	_	27	prep	27:A2=PRD
29	sale	sale	NN	_	28	pobj	_
30	in	in	IN	_	27	prep	27:AM-LOC
31	any	any	DT	_	32	det	_
32	market	market	NN	_	30	pobj	_
33	,	,	,	_	30	punct	_
34	or	or	CC	_	30	cc	_
35	at	at	IN	_	30	conj	_
36	any	any	DT	_	38	det	_
37	particular	particular	JJ	_	38	amod	_
38	time	time	NN	_	35	pobj	_
39	.	.	.	_	3	punct	_

1	Neither	neither	DT	p2=CC	4	nsubj	_
2	can	can	MD	_	4	aux	4:AM-MOD
3	there	there	EX	p2=RB	4	expl	_
4	be	be	VB	pb=be.02	0	root	_
5	any	any	DT	_	6	det	_
6	guarantee	guarantee	NN	_	4	attr	4:A1=PPT
7	that	that	IN	p2=WDT	15	complm	_
8	Lucentis	lucentis	NNP	p2=NNPS	26	nn	_
9	or	or	CC	_	8	cc	_
10	Lucentis	lucentis	NNP	p2=NNPS	8	conj	_
11	pre-filled	pre-filled	JJ	p2=VBD	12	amod	_
12	syringe	syringe	NN	_	15	nsubjpass	15:A1=PPT;17:A1=PPT
13	will	will	MD	_	15	aux	15:AM-MOD;17:AM-MOD
14	be	be	VB	_	15	auxpass	_
15	submitted	submit	VBN	pb=submit.01	6	ccomp	_
16	or	or	CC	_	15	cc	_
17	approved	approve	VBN	pb=approve.01	15	conj	_
18	for	for	IN	_	17	prep	17:AM-GOL
19	any	any	DT	_	21	det	_
20	additional	additional	JJ	_	21	amod	_
21	indications	indication	NNS	_	18	pobj	_
22	or	or	CC	_	21	cc	_
23	labeling	labeling	NN	p2=VBG	21	conj	_
24	in	in	IN	_	21	prep	_
25	any	any	DT	_	26	det	_
26	market	market	NN	_	24	pobj	_
27	,	,	,	_	18	punct	_
28	or	or	CC	_	18	cc	_
29	at	at	IN	_	18	conj	_
30	any	any	DT	_	32	det	_
31	particular	particular	JJ	_	32	amod	_
32	time	time	NN	_	29	pobj	_
33	.	.	.	_	4	punct	_

1	Nor	nor	CC	_	4	cc	4:AM-NEG
2	can	can	MD	_	4	aux	4:AM-MOD
3	there	there	EX	_	4	expl	_
4	be	be	VB	pb=be.02	0	root	_
5	any	any	DT	_	6	det	_
6	guarantee	guarantee	NN	_	4	attr	4:A1=PPT
7	that	that	IN	_	11	complm	_
8	such	such	JJ	_	9	amod	_
9	products	product	NNS	_	11	nsubj	11:A1=PPT
10	will	will	MD	_	11	aux	11:AM-MOD
11	be	be	VB	pb=be.01	6	ccomp	_
12	commercially	commercially	RB	_	13	advmod	_
13	successful	successful	JJ	_	11	acomp	11:A2=PRD
14	in	in	IN	_	11	prep	11:AM-TMP
15	the	the	DT	_	16	det	_
16	future	future	NN	_	14	pobj	_
17	.	.	.	_	4	punct	_

1	In	in	IN	_	6	prep	_
2	particular	particular	JJ	_	1	amod	_
3	,	,	,	_	6	punct	_
4	management	management	NN	p2=JJ	6	nsubj	_
5	`	`	``	p2=VBD	6	punct	_
6	s	s	VBZ	p2=IN	0	root	_
7	expectations	expectation	NNS	_	13	nsubjpass	8:A0;13:A1=PPT
8	regarding	regard	VBG	pb=regard.01	7	partmod	_
9	such	such	JJ	_	10	amod	_
10	products	product	NNS	_	8	dobj	8:A1
11	could	could	MD	_	13	aux	13:AM-MOD
12	be	be	VB	_	13	auxpass	_
13	affected	affect	VBN	pb=affect.01	6	ccomp	_
14	by	by	IN	p2=RP	13	agent	13:A0=PAG
15	,	,	,	_	14	punct	_
16	among	among	IN	_	93	prep	_
17	other	other	JJ	_	18	amod	_
18	things	thing	NNS	_	16	pobj	_
19	,	,	,	_	18	punct	_
20	the	the	DT	_	21	det	_
21	uncertainties	uncertainty	NNS	_	93	nsubj	_
22	inherent	inherent	JJ	_	21	amod	_
23	in	in	IN	_	22	prep	_
24	research	research	NN	_	23	pobj	_
25	and	and	CC	_	24	cc	_
26	development	development	NN	_	24	conj	_
27	,	,	,	_	21	punct	_
28	including	include	VBG	_	21	prep	_
29	unexpected	unexpected	JJ	_	32	amod	_
30	clinical	clinical	JJ	_	31	amod	_
31	trial	trial	NN	_	32	nn	_
32	results	result	NNS	_	28	pobj	_
33	and	and	CC	_	32	cc	_
34	additional	additional	JJ	_	35	amod	_
35	analysis	analysis	NN	_	32	conj	_
36	of	of	IN	_	35	prep	_
37	existing	exist	VBG	pb=exist.01	39	amod	_
38	clinical	clinical	JJ	_	39	amod	_
39	data	datum	NNS	_	36	pobj	37:A1=PAG
40	;	;	:	p2=,	93	punct	_
41	unexpected	unexpected	JJ	_	43	amod	_
42	regulatory	regulatory	JJ	_	43	amod	_
43	actions	action	NNS	_	39	conj	_
44	or	or	CC	_	43	cc	_
45	delays	delay	NNS	_	43	conj	_
46	or	or	CC	_	45	cc	_
47	government	government	NN	_	48	nn	_
48	regulation	regulation	NN	_	45	conj	_
49	generally	generally	RB	_	48	advmod	_
50	;	;	:	p2=,	43	punct	_
51	global	global	JJ	_	52	amod	_
52	trends	trend	NNS	_	43	conj	_
53	toward	toward	IN	_	52	prep	_
54	health	health	NN	_	55	nn	_
55	care	care	NN	_	57	nn	_
56	cost	cost	NN	_	57	nn	_
57	containment	containment	NN	_	53	pobj	_
58	,	,	,	_	52	punct	_
59	including	include	VBG	_	52	prep	_
60	ongoing	ongoing	JJ	_	62	amod	_
61	pricing	pricing	NN	_	62	nn	_
62	pressures	pressure	NNS	_	59	pobj	_
63	;	;	:	p2=,	62	punct	_
64	general	general	JJ	_	68	amod	_
65	economic	economic	JJ	_	68	amod	_
66	and	and	CC	_	65	cc	_
67	industry	industry	NN	_	65	conj	_
68	conditions	condition	NNS	_	93	nsubj	_
69	;	;	:	p2=,	93	punct	_
70	the	the	DT	_	71	det	_
71	company	company	NN	_	93	nsubj	93:A0=PAG
72	`	`	``	p2=POS	71	punct	_
73	s	s	TO	p2=VBZ	93	prep	_
74	ability	ability	NN	p2=VB	73	pobj	_
75	to	to	TO	_	76	aux	_
76	obtain	obtain	VB	pb=obtain.01	74	infmod	_
77	or	or	CC	_	76	cc	_
78	maintain	maintain	VB	pb=maintain.01	76	conj	_
79	proprietary	proprietary	JJ	_	82	amod	_
80	intellectual	intellectual	JJ	_	81	amod	_
81	property	property	NN	_	82	nn	_
82	protection	protection	NN	_	78	dobj	78:A1=PPT
83	;	;	:	p2=,	78	punct	_
84	unexpected	unexpected	JJ	_	86	amod	_
85	manufacturing	manufacturing	NN	_	86	nn	_
86	issues	issue	NNS	_	82	conj	_
87	,	,	,	_	86	punct	_
88	and	and	CC	_	86	cc	_
89	other	other	JJ	_	90	amod	_
90	risks	risk	NNS	_	86	conj	_
91	and	and	CC	_	90	cc	_
92	factors	factor	NNS	_	90	conj	_
93	referred	refer	VBD	p2=VBN|pb=refer.01	14	pcomp	_
94	to	to	IN	_	93	prep	93:A1=PPT
95	in	in	IN	_	94	prep	_
96	Novartis	novartis	NNP	_	97	nn	_
97	AG	ag	NNP	_	95	pobj	_
98	`	`	``	p2=POS	101	punct	_
99	s	s	JJ	p2=DT	101	amod	_
100	current	current	JJ	p2=NN	101	amod	_
101	Form	form	NN	p2=NNP	97	appos	_
102	20	0	CD	p2=NNP	104	hmod	_
103	-	-	HYPH	p2=:	104	hyph	_
104	F	f	NNP	p2=NN	101	appos	_
105	on	on	IN	_	101	prep	_
106	file	file	NN	p2=CD	105	pobj	_
107	with	with	IN	_	106	prep	_
108	the	the	DT	_	113	det	_
109	US	us	NNP	_	110	nn	_
110	Securities	security	NNPS	_	113	nn	_
111	and	and	CC	_	110	cc	_
112	Exchange	exchange	NNP	_	110	conj	_
113	Commission	commission	NNP	_	107	pobj	_
114	.	.	.	_	6	punct	_

1	Novartis	novartis	NNP	p2=NN	3	nsubj	3:A0=PAG;17:A0=PAG
2	is	be	VBZ	_	3	aux	_
3	providing	provide	VBG	pb=provide.01	0	root	_
4	the	the	DT	_	5	det	_
5	information	information	NN	_	3	dobj	3:A1=PPT
6	in	in	IN	_	5	prep	_
7	this	this	DT	_	9	det	_
8	press	press	NN	_	9	nn	_
9	release	release	NN	_	6	pobj	_
10	as	as	IN	_	3	prep	_
11	of	of	IN	_	10	prep	_
12	this	this	DT	_	13	det	_
13	date	date	NN	_	11	pobj	_
14	and	and	CC	_	3	cc	_
15	does	do	VBZ	_	17	aux	_
16	not	not	RB	_	17	neg	17:AM-NEG
17	undertake	undertake	VB	pb=undertake.01	3	conj	_
18	any	any	DT	_	19	det	_
19	obligation	obligation	NN	_	17	dobj	17:A1=PPT
20	to	to	TO	_	21	aux	_
21	update	update	VB	pb=update.01	19	infmod	_
22	any	any	DT	_	26	det	_
23	forward	forward	RB	_	25	hmod	_
24	-	-	HYPH	_	25	hyph	_
25	looking	look	VBG	_	26	amod	_
26	statements	statement	NNS	_	21	dobj	21:A1=PPT;27:A1
27	contained	contain	VBN	pb=contain.01	26	partmod	_
28	in	in	IN	_	27	prep	27:A0
29	this	this	DT	_	31	det	_
30	press	press	NN	_	31	nn	_
31	release	release	NN	_	28	pobj	_
32	as	as	IN	_	31	prep	_
33	a	a	DT	_	34	det	_
34	result	result	NN	_	32	pobj	_
35	of	of	IN	_	34	prep	_
36	new	new	JJ	_	37	amod	_
37	information	information	NN	_	35	pobj	_
38	,	,	,	_	37	punct	_
39	future	future	JJ	p2=NN	40	amod	_
40	events	event	NNS	_	37	conj	_
41	or	or	CC	_	40	cc	_
42	otherwise	otherwise	RB	_	40	conj	_
43	.	.	.	_	3	punct	_

